Imperial Innovations Group, the listed technology commercialisation and investment company, and The Capital Fund, $100 million Regional Venture Capital Fund for London, have co-invested invested more than $1 million in NanoBioDesign Ltd., a company developing a range of toxicity screening systems to speed up the drug discovery process.